Clinical-stage biotechnology company, PharmAust (ASX:PAA), announces that the first patient has been dosed in the Open-Label Extension study at Calvary Health Care Bethlehem, which will investigate the long-term safety, tolerability and efficacy of monepantel in patients with Motor Neurone Disease.
ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02772313-6A1193834